Scientists at the Food and Drug Administration endorsed the COVID-19 vaccine developed by Moderna as safe and efficacious on Tuesday, one day after the first doses of a competing vaccine from Pfizer and BioNTech were delivered across the United States.
The documents were released ahead of a Thursday meeting of outside experts convened by the FDA, the final step before regulators are all but sure to issue an emergency use authorization for the Moderna vaccine. Moderna has asked that its vaccine be authorized for people over 18; the Pfizer/BioNTech vaccine was authorized for people over 16.
The event is scheduled to start at 9 a.m. ET. Watch the meeting in the player above.
The FDA reviewers said that the two-dose vaccine “was highly effective” in preventing symptomatic COVID-19 from occurring “at least 14 days after the receipt of the second dose.”
Vaccine-related side effects, such as aches and pains, appeared more severe than with the Pfizer/BioNTech vaccine, though such comparisons should be made with caution and are in no way expected to slow the clearance of the vaccine or present major concerns. There was also preliminary evidence that the vaccine has some efficacy after one dose, and that it prevents asymptomatic COVID-19 cases — those that occur without a person ever feeling ill.
Moderna disclosed Nov. 30 that its vaccine decreased symptomatic COVID-19 infections by 94 percent in clinical trials, while also preventing more severe forms of the disease. But the release of FDA documents provides the most complete look yet at what is likely to be the second COVID-19 vaccine cleared for emergency use against the disease.
WATCH: HHS holds kickoff event for COVID-19 vaccine
At Thursday’s meeting of the Vaccines and Related Biological Products Advisory Committee, the agency will seek the opinions of outside experts who will vote on whether the benefits of the COVID-19 vaccine, mRNA-1273, outweigh its risks. Though the FDA does not have to follow the recommendations of these panels, it usually does.
Moderna previously disclosed clinical trial data showing that 185 cases of COVID-19 occurred in those who received a placebo injection, which was given to half the volunteers in its 30,000-person study. Just 11 cases occurred in those volunteers who received the vaccine.
There were 30 cases of severe COVID-19 in the placebo group of the study, with none in the vaccine group. One volunteer in the placebo group died of COVID-19, compared to none in the vaccine group.
About 10 percent of volunteers in Moderna’s trial identified as Black, while 20 percent were Hispanic or Latinx, 5 percent were Asian, and just under 1 percent were Native American. In September, Moderna slowed down the enrollment of its trial in an effort to include more participants from underrepresented racial and ethnic groups.
Like the Pfizer/BioNTech vaccine, mRNA-1273 utilizes a new technology that uses a synthetic version of messenger RNA or mRNA, a key messenger chemical that living things use as part of the process that turn DNA code into the proteins that make up all cells.
That both of these vaccines use this new technology is a vindication for Moderna, which raised billions of dollars from investors based on the potential for mRNA technology but until now had not delivered a product.
READ MORE: Poor countries may face long wait for vaccines despite promises
But the Moderna and Pfizer/BioNTech vaccines are not identical. One difference: Moderna’s vaccine tended to cause more vaccine reactions in clinical trials, such as fevers, aches, and chills, than the Pfizer/BioNTech vaccine.
Severe reactions — which would lead patients to be briefly impaired, but not hospitalized, appear more common with the Moderna vaccine than with the Pfizer/BioNTech one, although comparisons from different trials can be misleading. In the Moderna study, 15.8 percent of patients had a severe, or grade 3, reaction. Rates of fever and severe fever were similar between studies. In the Moderna study, 65.3 percent had fatigue, 9.7 percent of it severe; muscle pain occurred in 58 percent of patients, 9 percent severe; joint pain 42.8 percent, with 5.2 percent severe.
In the Pfizer/BioNTech study, 59 percent of volunteers reported fatigue, 4.6 percent of them severe. Muscle pain occurred in 37.3 percent of those receiving the Pfizer vaccine. Joint pain occurred in 21.9 percent of recipients.
However, there were also different side effects between the placebo groups in the two studies. Rates of fatigue were similar, at 23 percent, in both placebo groups; muscle pain occurred in 12.4 percent of placebo patients for Moderna and 8 percent for Pfizer/BioNTech, and joint pain in 10.8 percent for Moderna and 5.2 percent in the Pfizer/BioNTech.
These types of reactions are generally expected as a result of the immune response spurred by a vaccine, and are not likely to present an issue to regulators or to doctors administering the vaccine.
WATCH: Inside the attempt to build trust about the COVID-19 vaccine in Black communities
FDA reviewers also noted an imbalance in cases of Bell’s palsy, a temporary weakness in muscles in the face, which also occurred with the Pfizer vaccine. There will be monitoring for this side effect. As with the Pfizer/BioNTech vaccine, FDA reviewers noted data that could be an indication of mild allergic reactions. After the Pfizer/BioNTech vaccine started being given in the United Kingdom, there were two reports of severe allergic reactions that had not been seen in clinical trials, leading to increased concern about those side effects.
Moderna said that it has conducted a developmental and reproductive toxicity study, used to assess giving a vaccine in pregnant women, with no adverse effects. Pfizer/BioNTech are still conducting such a study.
One encouraging finding with the Pfizer/BioNTech vaccine was that it appeared possible a single dose of the vaccine was effective in preventing COVID-19. Moderna is presenting a different analysis of the same question, looking at COVID-19 tests that were administered to patients at their first and second doses of the vaccine.
At the second injection, there were 14 cases that tested positive for COVID-19 in the vaccine group, compared to 38 in the placebo group. None of these patients had symptoms. Although the numbers are small (there were more than 14,000 patients in each group) they may indicate that one dose of the vaccine is somewhat effective in preventing the disease, and that the vaccine prevents asymptomatic cases.
This story was originally published by STAT News on Dec. 15, 2020. You can find the original article here.
"emergency" - Google News
December 17, 2020 at 09:18AM
https://ift.tt/3gXauNy
WATCH LIVE: FDA advisers consider Moderna’s COVID-19 vaccine for emergency use - PBS NewsHour
"emergency" - Google News
https://ift.tt/2VVGGYQ
https://ift.tt/3d7MC6X
emergency
Bagikan Berita Ini
0 Response to "WATCH LIVE: FDA advisers consider Moderna’s COVID-19 vaccine for emergency use - PBS NewsHour"
Post a Comment